Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.087
Sell
RSI(14)
17.211
Oversold
STOCH(KDJ)(9,3,3)
28.700
Neutral
ATR(14)
0.227
Low Volatility
CCI(14)
-102.697
Sell
Williams %R
77.099
Sell
TRIX(12,20)
-2.402
Sell
StochRSI(14)
9.929
Sell
Search
Biodexa Pharmaceuticals PLC
BDRXAdd to Watchlist
1.310USD
-0.170-11.49%
Close 07-31 16:00（ET）Quotes delayed by 15 min
591.64KMarket Cap
7.51P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-11.49%
5 Days
-20.61%
1 Month
-56.33%
6 Months
-25.99%
Year to Date
-42.29%
1 Year
-83.31%
Key Figures
1.480Open
1.480High
25.61KVolume
7.51P/E TTM
LossP/E Dynamic
--Dividend TTM
5.67%Turnover Ratio
1.480Prev. Close
1.260Low
20.03KTurnover
LossP/E Static
0.07P/B
0.00%Div Yield TTM
-43.26%ROA
66.50052wk High
0.36Volume Ratio
-5.73MNet Profit
451.64KShares
0.1743EPS TTM
1.22Beta
-61.77%ROE
2.86052wk Low
14.86%Amplitude
--Gross Margin
591.64KMarket Cap
-7.03Reward/Risk
7.06%Risk Rate
Biodexa Pharmaceuticals PLC News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
0
analysts
--
Current Rating
10.000
Target Price
+592.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Biodexa Pharmaceuticals PLC
BDRX
0
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.451
Sell
MA10
1.620
Sell
MA20
2.025
Sell
MA50
2.674
Sell
MA100
2.803
Sell
MA200
3.240
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biodexa Pharmaceuticals PLC Info
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Ticker SymbolBDRX
CompanyBiodexa Pharmaceuticals PLC
CEOStamp (Stephen A)
Websitehttps://www.biodexapharma.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Biodexa Pharmaceuticals PLC (BDRX)?
The current price of Biodexa Pharmaceuticals PLC (BDRX) is 1.31.
What is the symbol of Biodexa Pharmaceuticals PLC?
The ticker symbol of Biodexa Pharmaceuticals PLC is BDRX.
What is the 52-week high of Biodexa Pharmaceuticals PLC?
The 52-week high of Biodexa Pharmaceuticals PLC is 66.50.
What is the 52-week low of Biodexa Pharmaceuticals PLC?
The 52-week low of Biodexa Pharmaceuticals PLC is 2.86.
What is the market capitalization of Biodexa Pharmaceuticals PLC?
The market capitalization of Biodexa Pharmaceuticals PLC is 591.64K.
What is the Earnings Per Share (EPS TTM) of Biodexa Pharmaceuticals PLC (BDRX)?
The Earnings Per Share (EPS TTM) of Biodexa Pharmaceuticals PLC (BDRX) is -80.84.